FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to oncology, and concerns the treatment of cancer. For this purpose, tumors sensitive to axitinib treatment are identified. To determine the sensitivity, measurement of the expression levels of the CD68 polypeptide in a tissue sample from a tumor, as well as the percentage of CD68-positive cells and the density of CD68-positive cells in the tumor are used.
EFFECT: this provides a high probability of determining the effectiveness or ineffectiveness of treatment with axitinib and, accordingly, choosing the most appropriate therapy for each particular patient.
15 cl, 2 ex, 11 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PROGNOSTIC FACTORS FOR TREATING CANCER | 2012 |
|
RU2600026C2 |
| BIOMARKERS FOR COMBINED THERAPY INCLUDING LENVATINIB AND EVEROLIMUS | 2016 |
|
RU2745060C2 |
| METHODS FOR CLASSIFYING PATIENTS WITH SOLID CANCER | 2017 |
|
RU2745730C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| METHOD FOR TREATING THRICE-NEGATIVE BREAST CANCER | 2017 |
|
RU2757905C2 |
| BIOMARKERS BASED ON TUMOR TISSUE FOR COMBINED THERAPY WITH BEVACIZUMAB | 2011 |
|
RU2605282C2 |
| BIOMARKERS FOR PREDICTING AND ASSESSING RESPONSIVENESS OF ENDOMETRIAL CANCER SUBJECTS TO LENVATINIB COMPOUNDS | 2014 |
|
RU2658601C2 |
| USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICINAL AGENT FOR TREATING SOLID TUMOURS | 2020 |
|
RU2825845C2 |
| TREATING LUNG CANCER BY COMBINATION OF ANTI-PD-1 AND OTHER ANTI-CANCER AGENTS | 2015 |
|
RU2695332C2 |
| BIOLOGICAL MARKERS FOR IDENTIFYING PATIENTS FOR TREATMENT WITH VEGF ANTAGONISTS | 2013 |
|
RU2659173C2 |
